Literature DB >> 9053798

Enkephalin terminals form inhibitory-type synapses on neurons in the rat nucleus locus coeruleus that project to the medial prefrontal cortex.

E J van Bockstaele1, E E Colago, V M Pickel.   

Abstract

Norepinephrine-containing fibres in the medial prefrontal cortex derive from the locus coeruleus, a brainstem nucleus which also receives a dense innervation of enkephalin-immunoreactive axon terminals. We combined immunogold-silver labelling of retrogradely transported FluoroGold from the medial prefrontal cortex with immunoperoxidase detection of leucine5-enkephalin in the same section of tissue through the locus coeruleus of adult rats. This dual-labelling experiment was conducted to determine whether axon terminals containing lecuine5-enkephalin target neurons in the locus coeruleus that project to the frontal cortex and, if so, what are their morphological characteristics. By light microscopy, enkephalin-labelled processes overlapped FluoroGold retrogradely labelled neurons in the locus coeruleus. By electron microscopy, retrogradely labelled perikarya and dendrites were commonly enveloped by astrocytic processes and received few afferents in the plane of section examined. However, at sites unoccupied by glial processes, abundant afferent input could be identified. In addition, some FluoroGold-labelled perikarya and dendrites lacked this glial ensheathment but were more frequently apposed by axon terminals. Of 163 FluoroGold-labelled perikarya and dendrites examined where enkephalin immunoreactivity was present in the neuropil, 42% were contacted by enkephalin-immunoreactive axon terminals. The peroxidase-labelled enkephalin terminals as well as the unlabelled terminals often contained both small, clear and large dense core vesicles. Both labelled and unlabelled terminals also formed primary symmetric synapses characteristic of inhibitory transmitters with retrogradely labelled perikarya and proximal dendrites. At times, more than one enkephalin-labelled terminal was found to converge on a common retrogradely labelled perikarya or dendrite. These results demonstrate cellular sites where enkephalin-containing afferents may directly modulate and most likely inhibit the activity of cortically projecting neurons in the locus coeruleus.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9053798     DOI: 10.1016/0306-4522(95)00432-7

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  6 in total

1.  Ultrastructural evidence for co-localization of corticotropin-releasing factor receptor and mu-opioid receptor in the rat nucleus locus coeruleus.

Authors:  Beverly A S Reyes; Julia D Glaser; Elisabeth J Van Bockstaele
Journal:  Neurosci Lett       Date:  2006-12-15       Impact factor: 3.046

2.  Noradrenergic excitation and inhibition of GABAergic cell types in rat frontal cortex.

Authors:  Y Kawaguchi; T Shindou
Journal:  J Neurosci       Date:  1998-09-01       Impact factor: 6.167

Review 3.  The locus coeruleus: A key nucleus where stress and opioids intersect to mediate vulnerability to opiate abuse.

Authors:  E J Van Bockstaele; B A S Reyes; R J Valentino
Journal:  Brain Res       Date:  2009-09-16       Impact factor: 3.252

4.  Corticotropin-releasing hormone receptors in the medial prefrontal cortex regulate hypothalamic-pituitary-adrenal activity and anxiety-related behavior regardless of prior stress experience.

Authors:  Azra Jaferi; Seema Bhatnagar
Journal:  Brain Res       Date:  2007-09-19       Impact factor: 3.252

5.  Ultrastructural analysis of rat ventrolateral periaqueductal gray projections to the A5 cell group.

Authors:  D Bajic; E J Van Bockstaele; H K Proudfit
Journal:  Neuroscience       Date:  2012-08-20       Impact factor: 3.590

6.  Hypocretin1/orexinA-immunoreactive axons form few synaptic contacts on rat ventral tegmental area neurons that project to the medial prefrontal cortex.

Authors:  Esther Del Cid-Pellitero; Miguel Garzón
Journal:  BMC Neurosci       Date:  2014-09-07       Impact factor: 3.288

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.